Poor tolerability of a transdermal nicotine treatment in Parkinson's disease

Clinical Neuropharmacology

Volumn 26, Issue 5, 2003, Pages 227-229

  Lemay, Simon ^a,b   Blanchet, Pierre ^b   Chouinard, Sylvain ^b   Masson, Hélène ^b   Soland, Valérie ^b   Bédard, Marc André ^a,b  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Nicotine; Parkinson's disease; Side effects; Transdermal patch

Indexed keywords

NICOTINE;

ABDOMINAL CRAMP; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTENSION; MALE; MOTOR DYSFUNCTION; MUSCLE WEAKNESS; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; TITRIMETRY; TRANSDERMAL PATCH; VERTIGO; VOMITING;

ADMINISTRATION, CUTANEOUS; AGED; CHI-SQUARE DISTRIBUTION; DIZZINESS; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NICOTINE; PARKINSON DISEASE; VOMITING;

EID: 0141867641     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200309000-00004     Document Type: Article

References (15)

1. Kelton MC, Kahn HJ, Conrath CL, et al. The effect of nicotine in Parkinson's disease. Brain Cogn. 2000;43:274-282.
2. Ebersbach G, Stöck M, Müller J, et al. Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration. Mov Disord. 1999;14:1011-1013.
3. Vieregge A, Sieberer M, Jacobs H, et al. Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study. Neurology. 2001;57:1032-1035.
4. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982;17:37-49.
5. Mattis S. Mental status examination for organic mental syndrome in the elderly patient. In: Bellak L, Karasu TB, eds. Geriatric Psychiatry. New York: Grune & Stratton; 1976:77-121.
6. Srivastava ED, Russell MAH, Feyerabend C, et al. Sensitivity and tolerance to nicotine in smokers and nonsmokers. Psychopharmacology (Berl). 1991;105:63-68.
7. Sandborn WJ. Nicotine therapy for ulcerative colitis: a review of rationale, mechanisms, pharmacology, and clinical results. Am J Gastroenterol. 1999;94:1161-1171.
8. Sandborn WJ, Tremaine WJ, Offord KP, et al. Transdermal nicotine for mildly to moderately active ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997;126:364-371.
9. Thomas GAO, Rhodes J, Mani V, et al. Transdermal nicotine as maintenance therapy for ulcerative colitis. N Engl J Med. 1995;332:988-992.
10. Pullan RD, Rhodes J, Ganesh S. Transdermal nicotine for active ulcerative colitis. N Engl J Med. 1994;330:811-815.
11. Thomas GA, Rhodes J, Ragunath K, et al. Transdermal nicotine compared with oral prednisolone therapy for active ulcerative colitis. Eur J Gastroenterol Hepatol. 1996;8:769-776.
12. Fant RV, Henningfield JE, Shiffman S. A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches. Pharmacol Biochem Behav. 2000;67:479-482.
13. Henningfield JE. Nicotine medications for smoking cessation. N Engl J Med. 1995;333:1196-1203.
14. Perry EK, Morris CM, Court JA, et al. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience. 1995;64:385-395.
15. Schneider JS, Tinker JP, Velson MV, et al. Nicotinic acetylcholine receptor agonist SIB-1508Y improved cognitive functioning in chronic low-dose MPTP-treated monkeys. J Pharmacol Exp Ther. 1999;290:731-739.